Healthcare entity
Of the tracked stories, 2 of 2 also mention BARDA, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention BARDA, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. Spectral AI, Inc. appears in 2 tracked Healthcare stories published from March 19, 2026 through March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 129 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Spectral AI, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Commercial Target
Anticipated focus on commercial scaling and market penetration for DeepView AI.
FY 2025 Earnings Release
Company reports $19.7M in total R&D revenue for the full year.
2026 Guidance Introduced
Management provides first-ever revenue guidance for the upcoming fiscal year.
Year-End Cash Position
Spectral AI closes the year with $15.4 million in cash and equivalents.
Spectral AI reported full-year 2025 research and development revenue of $19.7 million, driven by its DeepView AI platform. With a strengthened cash position of $15.4 million, the company has introduced its first revenue guidance for 2026 as it transitions toward commercialization.
Source: marketscreener.com · marketminute.com
Spectral AI has been awarded $31.7 million in non-dilutive funding from BARDA to accelerate the development and clinical validation of its DeepView® System. This investment aims to enhance AI-driven medical diagnostics for faster, more accurate wound care decisions, particularly in burn and diabetic foot ulcer management.
Source: GlobeNewswire · Benzinga
Spectral AI, Inc. is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
